Once the debt is completely repaid & we know what the net profit is per year we should not sell for less than 10x that. The profits are mostly recurring revenue from storage fees which will be steadily getting more and more. That is not even taking into account growth & potential in the biotech field overall. We shouldn't settle for anything less than 10x yearly profits.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.